The goals and objectives of this project are to evaluate the antileukemic activity of the
investigational agent clofarabine in patients with acute myelogenous leukemia (AML), acute
lymphocytic leukemia (ALL), and chronic myelogenous leukemia (CML) in accelerated and blastic
phases.